Notably, our study demonstrates that IHC analysis of CXCL13+ cells can predict favorable and unfavorable prognostic in NSCLC patients undergoing Pembrolizumab/Nivolumab treatment. The gene discussed is CXCL13; the disease is non-small cell lung carcinoma.